JPS6247880B2 - - Google Patents

Info

Publication number
JPS6247880B2
JPS6247880B2 JP51061032A JP6103276A JPS6247880B2 JP S6247880 B2 JPS6247880 B2 JP S6247880B2 JP 51061032 A JP51061032 A JP 51061032A JP 6103276 A JP6103276 A JP 6103276A JP S6247880 B2 JPS6247880 B2 JP S6247880B2
Authority
JP
Japan
Prior art keywords
freon
microns
flunisolide
particle size
propellant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP51061032A
Other languages
English (en)
Japanese (ja)
Other versions
JPS51144719A (en
Inventor
Eichi Furiido Jon
Ii Joonzu Richaado
Teii Haringaa Gisera
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syntex USA LLC
Original Assignee
Syntex USA LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syntex USA LLC filed Critical Syntex USA LLC
Publication of JPS51144719A publication Critical patent/JPS51144719A/ja
Publication of JPS6247880B2 publication Critical patent/JPS6247880B2/ja
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/0026—Oxygen-containing hetero ring cyclic ketals
    • C07J71/0031—Oxygen-containing hetero ring cyclic ketals at positions 16, 17

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
JP51061032A 1975-05-27 1976-05-26 Preparation of crystalline frunisolide and ittcontaining composition Granted JPS51144719A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58130075A 1975-05-27 1975-05-27
US58130175A 1975-05-27 1975-05-27

Publications (2)

Publication Number Publication Date
JPS51144719A JPS51144719A (en) 1976-12-13
JPS6247880B2 true JPS6247880B2 (enExample) 1987-10-09

Family

ID=27078279

Family Applications (1)

Application Number Title Priority Date Filing Date
JP51061032A Granted JPS51144719A (en) 1975-05-27 1976-05-26 Preparation of crystalline frunisolide and ittcontaining composition

Country Status (15)

Country Link
JP (1) JPS51144719A (enExample)
AT (1) AT357702B (enExample)
AU (1) AU506080B2 (enExample)
CA (1) CA1075228A (enExample)
DE (2) DE2661037C2 (enExample)
ES (1) ES448220A1 (enExample)
FR (1) FR2361900A1 (enExample)
GB (1) GB1525181A (enExample)
HK (1) HK8580A (enExample)
IL (1) IL49652A (enExample)
MX (1) MX3864E (enExample)
MY (1) MY8000275A (enExample)
NL (1) NL191234C (enExample)
NZ (1) NZ180946A (enExample)
SE (1) SE421426B (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2457303A1 (fr) * 1979-05-21 1980-12-19 Syntex Corp Procede de preparation d'une forme cristalline de flunisolide, le produit obtenu et son utilisation comme produit pharmaceutique
EP0039369B1 (en) * 1980-05-02 1983-06-15 Schering Corporation Beclomethasone ester solvates, process for their preparation, and preparation of a formulation
GB2127689B (en) * 1982-10-05 1986-07-09 Sandoz Ltd Calcitonin inhalation compositions
US4782047A (en) * 1986-05-22 1988-11-01 Syntex Pharmaceuticals International Ltd. Aqueous steroid formulations for nasal administration
JP2843857B2 (ja) * 1988-10-05 1999-01-06 ファルマシア・アンド・アップジョン・カンパニー 反溶剤への沈澱を介する微細分化固体結晶性粉末
US5707634A (en) * 1988-10-05 1998-01-13 Pharmacia & Upjohn Company Finely divided solid crystalline powders via precipitation into an anti-solvent
DE4003272A1 (de) 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgasmischungen und ihre verwendung in arzneimittelzubereitungen
RU2223750C2 (ru) * 1995-06-27 2004-02-20 Берингер Ингельхайм КГ Лекарственная композиция в виде раствора, предназначенная для получения способного к ингаляции аэрозоля
DE19653969A1 (de) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg Neue wässrige Arzneimittelzubereitung zur Erzeugung treibgasfreier Aerosole
US20010031244A1 (en) 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
DZ2947A1 (fr) 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
HK1039459B (en) * 1999-03-03 2005-05-13 Optinose As Nasal delivery device
IT1313553B1 (it) 1999-07-23 2002-09-09 Chiesi Farma Spa Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione.
IT1317846B1 (it) 2000-02-22 2003-07-15 Chiesi Farma Spa Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva.
IL152955A0 (en) 2000-05-22 2003-06-24 Chiesi Farma Spa Stable pharmaceutical solution formulations for pressurised metered dose inhalers
DE60103527T2 (de) 2001-07-02 2005-06-16 Chiesi Farmaceutici S.P.A. Optimierte Tobramycin-Formulierung zur Aerosolbildung
JP4632687B2 (ja) * 2003-04-25 2011-02-16 ロート製薬株式会社 点鼻剤
JP5238779B2 (ja) * 2003-04-25 2013-07-17 ロート製薬株式会社 点鼻剤
EP1595531A1 (en) 2004-05-13 2005-11-16 CHIESI FARMACEUTICI S.p.A. Stable pharmaceutical solution formulations for pressurized metered dose inhalers
EP2968572A1 (en) 2013-03-15 2016-01-20 Medicis Pharmaceutical Corporation Topical compositions of flunisolide and methods of treatment

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3126375A (en) * 1964-03-24 Chioacyl
GB933867A (en) * 1958-12-08 1963-08-14 American Cyanamid Co Fluorinated steroids
US3282791A (en) * 1965-08-17 1966-11-01 Merck & Co Inc Inhalation aerosol suspension of anhydrous disodium dexamethasone phosphate, propellents, and sorbitan trioleate
US3592930A (en) 1968-07-19 1971-07-13 Syntex Corp Moisture-deterioratable topical medicaments,particularly anti-inflammatory steroids,in a substantially non-aqueous fatty alcohol-propylene glycol vehicle
FR2038105A1 (fr) * 1969-04-01 1971-01-08 Syntex Corp Composition anti-inflammatoire locale et son mode d'utilisation
GB1429184A (en) * 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
DE2332663C2 (de) * 1973-06-23 1986-07-31 Schering AG, 1000 Berlin und 4709 Bergkamen Verwendung von Kortikoid-Wirkstoffen zur Inhalationstherapie
US3934013A (en) 1975-02-21 1976-01-20 Syntex (U.S.A.) Inc. Pharmaceutical composition

Also Published As

Publication number Publication date
NL191234B (nl) 1994-11-01
IL49652A0 (en) 1976-07-30
DE2624924C2 (de) 1986-11-27
JPS51144719A (en) 1976-12-13
MY8000275A (en) 1980-12-31
AT357702B (de) 1980-07-25
AU1430176A (en) 1977-12-01
ATA388376A (de) 1979-12-15
FR2361900B1 (enExample) 1979-04-13
DE2624924A1 (de) 1977-12-15
SE421426B (sv) 1981-12-21
FR2361900A1 (fr) 1978-03-17
CA1075228A (en) 1980-04-08
ES448220A1 (es) 1977-11-01
IL49652A (en) 1979-05-31
SE7605927L (sv) 1976-11-28
AU506080B2 (en) 1979-12-13
NZ180946A (en) 1978-07-28
HK8580A (en) 1980-03-14
NL191234C (nl) 1995-04-03
NL7605699A (nl) 1976-11-30
GB1525181A (en) 1978-09-20
MX3864E (es) 1981-08-26
DE2661037C2 (enExample) 1989-04-06

Similar Documents

Publication Publication Date Title
JPS6247880B2 (enExample)
JP4672143B2 (ja) 医薬用エーロゾル製剤
US4364923A (en) Chemical compounds
JP4570251B2 (ja) 医薬用エーロゾル製剤
RU2294737C2 (ru) Медицинские аэрозольные составы
JP2020073516A5 (enExample)
JP2020073515A5 (enExample)
US9889094B2 (en) Particle size reduction of an antimuscarinic compound
WO1998034595A1 (de) Medizinische aerosolformulierungen
JPH09506896A (ja) フルニゾリド・エアロゾル配合品
US5891419A (en) Environmentally safe flunisolide aerosol formulations for oral inhalation
PT1572153E (pt) Preparação de suspensões aquosas estéreis que compreendem princípios activos cristalinos micronizados para inalação
JP3264496B2 (ja) クロロフルオロカーボンを含まないモメタゾンフロエートエーロゾルの処方物
US20030190289A1 (en) Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases
US20120207685A1 (en) Non-ozone depleting medicinal formulations with low greenhouse effect
US4933168A (en) Stable, crystalline flunisolide
US20150080358A1 (en) Pharmaceutical Composition
ME00247B (me) Formulacije hfa-suspenzija koje sadrže antiholinergik
JPS62281817A (ja) 鼻用噴霧液
CA1083963A (en) Use of flunisolide to treat respiratory diseases
US10993879B2 (en) Pulmonary delivery of progestogen
BR102012008322A2 (pt) Formulações medicinais em aerossol que não debilitam a camada de ozônio e com baixo efeito estufa
HK1216302B (zh) 抗毒蕈硷化合物的粒度减小
HK1064295B (en) Medical aerosol formulations